---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-026316"
form_type: "8-K"
ticker: "KAPA"
cik: "0001962011"
company_name: "Kairos Pharma, LTD."
filed_at: "2025-09-03T23:59:59+00:00"
generated_at: "2026-05-17T08:39:39.156013+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Kairos Pharma to present initial Phase 1 data for ENV105 in NSCLC at World Lung Cancer Conference

## Summary
- Dr. Karen Reckamp to present combination of ENV105 (carotuximab) with osimertinib for advanced EGFR-mutated NSCLC.
- Presentation at World Lung Cancer Conference in Barcelona, Spain, September 6-9, 2025.
- Primary objective of open-label Phase 1 trial is to evaluate safety and tolerability of the combination.
- ENV105 targets CD105 to reverse drug resistance; also in Phase 2 for castrate-resistant prostate cancer.

## SEC filing metadata
- accession: 0001641172-25-026316
- form_type: 8-K
- ticker: KAPA
- cik: 0001962011
- company_name: Kairos Pharma, LTD.
- filed_at: 2025-09-03T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1962011/000164117225026316/0001641172-25-026316-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1962011/000164117225026316/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-026316
- JSON: https://secwatch.observer/filing/0001641172-25-026316.json
- Plain text: https://secwatch.observer/filing/0001641172-25-026316.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.